Suppr超能文献

蛋白酶激活受体-2的免疫调节作用。

Immunomodulatory role of proteinase-activated receptor-2.

机构信息

School of Science, University of the West of Scotland, Paisley PA1 2BE, Scotland, UK.

出版信息

Ann Rheum Dis. 2012 Sep;71(9):1559-66. doi: 10.1136/annrheumdis-2011-200869. Epub 2012 May 6.

Abstract

OBJECTIVE

Proteinase-activated receptor-2 (PAR(2)) has been implicated in inflammatory articular pathology. Using the collagen-induced arthritis model (CIA) the authors have explored the capacity of PAR(2) to regulate adaptive immune pathways that could promote autoimmune mediated articular damage.

METHODS

Using PAR(2) gene deletion and other approaches to inhibit or prevent PAR(2) activation, the development and progression of CIA were assessed via clinical and histological scores together with ex vivo immune analyses.

RESULTS

The progression of CIA, assessed by arthritic score and histological assessment of joint damage, was significantly (p<0.0001) abrogated in PAR(2) deficient mice or in wild-type mice administered either a PAR(2) antagonist (ENMD-1068) or a PAR(2) neutralising antibody (SAM11). Lymph node derived cell suspensions from PAR(2) deficient mice were found to produce significantly less interleukin (IL)-17 and IFNγ in ex vivo recall collagen stimulation assays compared with wild-type littermates. In addition, substantial inhibition of TNFα, IL-6, IL-1β and IL-12 along with GM-CSF and MIP-1α was observed. However, spleen and lymph node histology did not differ between groups nor was any difference detected in draining lymph node cell subsets. Anticollagen antibody titres were significantly lower in PAR(2) deficient mice.

CONCLUSION

These data support an important role for PAR(2) in the pathogenesis of CIA and suggest an immunomodulatory role for this receptor in an adaptive model of inflammatory arthritis. PAR(2) antagonism may offer future potential for the management of inflammatory arthritides in which a proteinase rich environment prevails.

摘要

目的

蛋白酶激活受体-2(PAR(2))与炎症性关节病理有关。作者利用胶原诱导关节炎模型(CIA)探索 PAR(2)调节适应性免疫途径的能力,这些途径可能促进自身免疫介导的关节损伤。

方法

通过 PAR(2)基因缺失和其他抑制或预防 PAR(2)激活的方法,通过临床和组织学评分以及体外免疫分析评估 CIA 的发展和进展。

结果

PAR(2)缺陷小鼠或给予 PAR(2)拮抗剂(ENMD-1068)或 PAR(2)中和抗体(SAM11)的野生型小鼠中,CIA 的进展(通过关节炎评分和关节损伤的组织学评估来评估)显著(p<0.0001)减轻。与野生型同窝小鼠相比,PAR(2)缺陷小鼠的淋巴结来源细胞悬浮液在体外回忆性胶原刺激试验中产生的白细胞介素(IL)-17 和 IFNγ明显减少。此外,还观察到 TNFα、IL-6、IL-1β 和 IL-12 以及 GM-CSF 和 MIP-1α 的大量抑制。然而,各组之间的脾和淋巴结组织学没有差异,也没有检测到引流淋巴结细胞亚群的差异。抗胶原抗体滴度在 PAR(2)缺陷小鼠中显著降低。

结论

这些数据支持 PAR(2)在 CIA 发病机制中的重要作用,并表明该受体在适应性炎症性关节炎模型中具有免疫调节作用。PAR(2)拮抗作用可能为富含蛋白酶的环境中存在的炎症性关节炎的管理提供未来的潜力。

相似文献

1
Immunomodulatory role of proteinase-activated receptor-2.
Ann Rheum Dis. 2012 Sep;71(9):1559-66. doi: 10.1136/annrheumdis-2011-200869. Epub 2012 May 6.
2
Evaluation of protease-activated receptor 2 in murine models of arthritis.
Arthritis Rheum. 2007 Jan;56(1):101-7. doi: 10.1002/art.22312.
4
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.
Arthritis Rheum. 2009 Mar;60(3):738-49. doi: 10.1002/art.24305.
8
Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33.
Arthritis Res Ther. 2016 Jun 18;18(1):143. doi: 10.1186/s13075-016-1042-x.
10
Decreased collagen-induced arthritis severity and adaptive immunity in MKK-6-deficient mice.
Arthritis Rheum. 2012 Mar;64(3):678-87. doi: 10.1002/art.33359.

引用本文的文献

1
A New Strategy in Modulating the Protease-Activated Receptor 2 (Par2) in Autoimmune Diseases.
Int J Mol Sci. 2025 Jan 6;26(1):410. doi: 10.3390/ijms26010410.
2
1-Piperidine Propionic Acid Protects from Septic Shock Through Protease Receptor 2 Inhibition.
Int J Mol Sci. 2024 Oct 30;25(21):11662. doi: 10.3390/ijms252111662.
5
Matriptase drives dissemination of ovarian cancer spheroids by a PAR-2/PI3K/Akt/MMP9 signaling axis.
J Cell Biol. 2023 Nov 6;222(11). doi: 10.1083/jcb.202209114. Epub 2023 Sep 22.
7
Protease Activated Receptors and Arthritis.
Int J Mol Sci. 2021 Aug 28;22(17):9352. doi: 10.3390/ijms22179352.
8
Proteinase-Mediated Macrophage Signaling in Psoriatic Arthritis.
Front Immunol. 2021 Mar 8;11:629726. doi: 10.3389/fimmu.2020.629726. eCollection 2020.
10
Rheumatic Disease: Protease-Activated Receptor-2 in Synovial Joint Pathobiology.
Front Endocrinol (Lausanne). 2018 May 23;9:257. doi: 10.3389/fendo.2018.00257. eCollection 2018.

本文引用的文献

1
PAR(2) expression in peripheral blood monocytes of patients with rheumatoid arthritis.
Ann Rheum Dis. 2012 Jun;71(6):1049-54. doi: 10.1136/annrheumdis-2011-200703. Epub 2012 Jan 30.
3
Correlation of protease-activated receptor-2 expression and synovitis in rheumatoid and osteoarthritis.
Rheumatol Int. 2012 Oct;32(10):3077-86. doi: 10.1007/s00296-011-2102-9. Epub 2011 Sep 13.
4
Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110).
Br J Pharmacol. 2012 Mar;165(5):1413-23. doi: 10.1111/j.1476-5381.2011.01610.x.
5
Novel agonists and antagonists for human protease activated receptor 2.
J Med Chem. 2010 Oct 28;53(20):7428-40. doi: 10.1021/jm100984y.
6
Protease-activated receptor 2 signalling promotes dendritic cell antigen transport and T-cell activation in vivo.
Immunology. 2010 Jan;129(1):20-7. doi: 10.1111/j.1365-2567.2009.03144.x. Epub 2009 Jun 22.
7
Critical regulation of early Th17 cell differentiation by interleukin-1 signaling.
Immunity. 2009 Apr 17;30(4):576-87. doi: 10.1016/j.immuni.2009.02.007. Epub 2009 Apr 9.
9
Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics.
Immunol Rev. 2008 Jun;223:7-19. doi: 10.1111/j.1600-065X.2008.00626.x.
10
Protocol for the induction of arthritis in C57BL/6 mice.
Nat Protoc. 2008;3(4):612-8. doi: 10.1038/nprot.2008.19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验